Anti-Parkinsons Flashcards
Drugs and Chemicals that may cause Parkinsons
Antipsychotics (Haloperidol)
MPTP
Alpha Synuclein Protein
Dopamine Precursor
L Dopa
Dopamine Receptor Antagonists
Pramipexole
Ropinirole
Bromocriptine
Apomorphine
MAOI
Selegiline
Rasagiline
COMT Inhibitors
Entacapone
Tolcapone
Dopamine Facilitators
Amantadine
CNS Anticholinergic Agents
Benztropine
Trihexyphenidyl
Carbidopa
- Inhibits DOPA Decarboxylase BUT cannot cross BBB
DOPA Decarboxylase Co-Factor
Pyridoxine
L Dopa
- Prodrug of Dopamine
- Stimulates D2 receptors
PHARMACOKINETICS: Mostly metabolized cereberally, given in combo w/ Carbidopa to prevent peripheral metabolism
L Dopa: Clinical & Pharmacologic Effects
CLINICAL
- Best Results in first few years of Tx
- Works faster on rigidity and bradykinesia than on tremor
PHARMACOLOGIC
- Tolerance to effects builds up after 5 years
- Effective in relieving Bradykinesia
L Dopa: GI Effects
- Anorexia, Nausea/Vomiting at first (tolerance builds up)
- Avoid Antiemetics
- GI effects less frequent w/ L Dopa/Carbidopa combo
L Dopa: SE
CVS - Arrhythmias, Tachycardia, postural hypotension BEHAVIORAL - Depression, Anxiety, Agitation, Insomnia, Confusion, Hallucinations, Nightmare, Euphoria DYSKINESIA - Choreoathetosis RESPONSE FLUCTUATIONS - Wearing-off Rxns (End Dose Akinesia) - On-Off Phenomena MISC - Mydriasis, Glaucoma (maybe) - Brown saliva, urine, vaginal secretions
L DOPA: Drug Interactions and CI
DRUG INTERACTIONS
- L DOPA + MAOI = HTN Crisis, Hyperpyrexia
- L DOPA + Pyridoxine = Peripheral conversion of L DOPA to Dopamine
- Antiemetics = Block Dopamine Receptors
CI
- Psychotic Pts
- Angle Closure Glaucoma
- Peptic Ulcer
- Melanoma& Skin Lesions
Carbidopa
- DOPA Decarboxylase Inhibitors
- Can’t Breach BBB
- Usually Combo w/ L DOPA